Group 1 - The China Securities Hong Kong Stock Connect Medical Theme Index (932069) has risen by 2.99%, with notable increases in constituent stocks such as Chunli Medical (01858) up 10.49%, MicroPort Medical (00853) up 7.02%, and Crystal Technology Holdings (02228) up 6.89% [1] - The Hong Kong Medical ETF (159366) has also seen an increase of 2.44% [1] - The China Securities All Index Medical Device Index (H30217) has increased by 1.46%, with significant gains from Ji Min Health (603222) up 9.98%, Hualan Biological Engineering (301093) up 7.81%, and Huatai Medical (688617) up 6.93% [2][3] Group 2 - The FDA has accepted Vibration-Controlled Transient Elastography (VCTE) as an alternative endpoint for assessing liver fibrosis in patients with Metabolic Associated Steatotic Liver Disease (MASH), marking a significant breakthrough in non-invasive diagnostic technology [4] - This advancement is expected to enhance drug development efficiency for MASH and provide growth opportunities for domestic companies in the non-invasive companion diagnostics field [4] - The pharmaceutical and biotechnology sector showed marginal improvement in Q2 2025, with the innovative drug and CXO sectors performing particularly well, as the CXO industry rebounded with a 14% year-on-year revenue increase and a 54% increase in net profit [4] Group 3 - The domestic medical device industry is gradually recovering from an adjustment period, with market demand showing signs of recovery [5] - In Q2 2025, the medical equipment sector experienced a 5.26% year-on-year revenue growth, and the medical consumables sector maintained stable growth [5] - The Hong Kong Medical ETF (159366) focuses on rare medical segment leaders and has a high CXO content, while the Medical Device ETF (159883) is the largest in A-shares, covering various sub-sectors of the medical device industry [5]

Core Viewpoint - Xiangyu Medical (688626.SH) has shown significant growth in the rehabilitation medical device industry, with a focus on brain-computer interface technology and a strong commitment to research and development [1][2][4]. Financial Performance - In the first half of 2025, the company achieved total revenue of 359 million yuan, with 173 million yuan in the second quarter, and a net profit attributable to shareholders of 35.39 million yuan [1]. Industry Position - Xiangyu Medical is one of the few comprehensive enterprises in China's rehabilitation medical device sector, providing products, integrated clinical rehabilitation solutions, and professional technical support [1]. - The company is recognized as one of the first "little giant" enterprises in the national specialized and innovative category [1]. Technological Development - The company has made early investments in brain-computer interface technology, focusing on non-invasive applications in rehabilitation [2]. - In the first half of 2025, the company invested 91.15 million yuan in research and development, accounting for 25.39% of total revenue, with a year-on-year increase of 38.8% [4][5]. - The company has filed for 117 new patents, bringing the total to 1,933, including 22 new invention patents [5]. Market Outlook - The rehabilitation medical device industry is projected to exceed 220 billion yuan in total revenue by 2025, indicating strong market demand [7]. - The brain-computer interface market is expected to reach 3.8 billion yuan by 2025 and 5.58 billion yuan by 2027, with a compound annual growth rate of 20% [7]. - Long-term projections suggest that the brain-computer interface market in China could surpass 120 billion yuan by 2040, with a compound annual growth rate of 26% [7]. Strategic Collaborations - The company has established partnerships with universities and research institutions for the development and transformation of brain-computer interface technologies [3]. - Xiangyu Medical has launched 13 brain-computer interface devices at recent industry forums, gaining significant attention [6].

Meeting Overview - The third meeting of the Supervisory Board of Henan Xiangyu Medical Equipment Co., Ltd. was held on August 27, 2025, with all three supervisors present [1][2]. Resolutions Passed - The Supervisory Board unanimously approved the 2025 semi-annual report, confirming that it complies with relevant laws and accurately reflects the company's financial status and operational results [1][2]. - The board approved the increase of expected daily related transactions for 2025, stating that these transactions are necessary for business development and will not adversely affect the company's financial condition [2][3]. - The board approved the use of excess raised funds to replace self-raised funds previously invested in construction projects, confirming that this action adheres to regulatory requirements and does not harm shareholder interests [3][4]. - The board approved a special report on the storage and use of raised funds for the first half of 2025, confirming compliance with relevant regulations and proper disclosure of fund usage [4].

Core Viewpoint - The company is utilizing excess raised funds to replace previously invested self-raised funds for ongoing projects, ensuring compliance with regulatory requirements and maintaining the integrity of fundraising purposes [1][5][7]. Fundraising Overview - The company was approved to issue 40 million shares at a price of RMB 28.82 per share, raising a total of RMB 1,152.8 million, with a net amount of RMB 1,049.66 million after deducting issuance costs. The excess funds raised amounted to RMB 341.66 million [1][2]. Investment Project Details - The total investment for the planned projects is RMB 1,009.62 million, with adjusted investment amounts for specific projects, including the rehabilitation equipment research and exhibition center, which saw its total investment increase from RMB 146.73 million to RMB 228.73 million [2][3]. Use of Excess Funds - The company decided to use RMB 79.12 million of the excess funds for the construction of the rehabilitation medical device industrial park, specifically for the research center and related facilities. This decision was approved in the board meeting held on April 23, 2025 [3][4]. Replacement of Self-raised Funds - The company plans to replace RMB 12.91 million of self-raised funds that were previously invested in the rehabilitation medical device industrial park with the excess funds. This replacement was approved in the board meeting on August 27, 2025 [4][5]. Compliance and Verification - The supervisory board and the accounting firm confirmed that the use of excess funds complies with relevant regulations and does not affect the normal implementation of investment projects. The replacement of funds was verified by the accounting firm, ensuring adherence to regulatory standards [5][7][8].

Group 1 - The company reported a revenue of 359,046,551.97 yuan for the first half of 2025, representing a year-on-year growth of 6.27% [1] - The net profit attributable to shareholders of the listed company was 35,394,674.93 yuan, showing a year-on-year decline of 37.50% [1]

Group 1 - The core viewpoint of the article highlights that Xiangyu Medical (688626.SH) reported its mid-year results for 2025, showing a revenue of 359 million yuan, which represents a year-on-year growth of 6.27% [1] - The net profit attributable to shareholders of the parent company was 35.39 million yuan, reflecting a significant decline of 37.5% compared to the previous year [1] - The basic earnings per share (EPS) for the company stood at 0.23 yuan [1]

Group 1 - The core point of the article is that Xiangyu Medical (SH 688626) held its third board meeting on August 27, 2025, to review the agenda including the 2025 semi-annual report and its summary [1] - For the year 2024, Xiangyu Medical's revenue composition is 98.67% from medical devices and 1.33% from other businesses [1] - As of the report date, Xiangyu Medical has a market capitalization of 8.9 billion yuan [1]

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://aco.mof.gov.cn）"进行查 您可 河南翔宇医疗设备股份有限公司 使用超募资金置换预先投入自筹资金专项鉴证报告 | | 目录 | 页次 | | --- | --- | --- | | | 鉴证报告 | 1-3 | | ニ、 | 使用超募资金置换预先投入自筹资金专项说明 | 1-3 | 立信会计师事务所(特殊普通合伙) IBDO% BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 河南翔宇医疗设备股份有限公司 使用超募资金置换预先投入自筹资金 专项鉴证报告 信会师报字[2025]第 ZE10591 号 使用超募资金置换预先投入自筹资金专项鉴证报告 信会师报字[2025]第ZE10591号 河南翔宇医疗设备股份有限公司全体股东: 我们接受委托,对后附的河南翔宇医疗设备股份有限公司(以下 简称"翔宇医疗"或"贵公司"）管理层编制的截至2025年7月9日止《关 千使用超墓资金置换预先投入自筹资金的专项说明》进行专项鉴证。 一、董事会的责任 翔宇医疗董事会的责任是按照中国证券监督 ...

国泰海通证券股份有限公司 关于河南翔宇医疗设备股份有限公司 使用超募资金置换预先投入自筹资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为河 南翔宇医疗设备股份有限公司（以下简称"翔宇医疗"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规 定，对翔宇医疗使用超募资金置换预先投入的自筹资金事项进行了核查，具体核 查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 1 月 26 日出具的《关于同意河南翔 宇医疗设备股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕254 号），公司获准向社会公众发行人民币普通股（A 股）40,000,000 股，每股发行 价格为人民币 28.82 元，本次发行募集资金总额 1,152,800,000.00 元；扣除发行 费用后，募集资金净额为 1,049,656,554.20 元，其中，超额募集资金金额为人民 币 34 ...

河南翔宇医疗设备股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》、《上海证券交易所科创板股票上市规 则》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 相关规定，河南翔宇医疗设备股份有限公司（以下简称"公司"）就 2025 年半 年度募集资金存放与使用情况作如下专项报告： 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-046 一、募集资金基本情况 （一）实际募集资金金额及资金到账情况 根据中国证券监督管理委员会于 2021 年 1 月 26 日出具的《关于同意河南翔 宇医疗设备股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕254 号），公司向社会公众发行人民币普通股（A 股）40,000,000 股，每股发行价格 为人民币 28.82 元，共募集资金为 1,152,800,000.00 元，扣除保荐承销费（不 含税）人民币 79,390,400.00 元，余款 1,07 ...